Details of the Drug

General Information of Drug (ID: DMDINC4)

Drug Name

Thiothixene

Synonyms

Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1], [2]

Therapeutic Class

Antipsychotic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

443.6

Topological Polar Surface Area (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 10 - 20 hours [3]
Metabolism: The drug is metabolized via the hepatic [4]

Chemical Identifiers

Formula: C23H29N3O2S2
IUPAC Name: (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
Canonical SMILES: CN1CCN(CC1)CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
InChI: InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
InChIKey: GFBKORZTTCHDGY-UWVJOHFNSA-N

Cross-matching ID

PubChem CID: 941651
ChEBI ID: CHEBI:9571
CAS Number: 3313-26-6
DrugBank ID: DB01623
TTD ID: D0E0LQ
INTEDE ID: DR1584
ACDINA ID: D00680

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thiothixene

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Iloperidone.	Schizophrenia [6A20]	[27]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Asenapine.	Schizophrenia [6A20]	[27]
-----------

Coadministration of a Drug Treating the Disease Different from Thiothixene (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Thiothixene and Oliceridine.	Acute pain [MG31]	[28]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[29]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[29]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Cariprazine.	Bipolar disorder [6A60]	[27]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Thiothixene when combined with Acetylcholine.	Cataract [9B10]	[30]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[31]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[31]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Thiothixene and Cyclandelate.	Dementia [6D80-6D8Z]	[32]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Thiothixene and OPC-34712.	Depression [6A70-6A7Z]	[27]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Thiothixene and Esketamine.	Depression [6A70-6A7Z]	[33]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Mepenzolate.	Digestive system disease [DE2Z]	[27]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Thiothixene and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[34]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Thiothixene and Deutetrabenazine.	Dystonic disorder [8A02]	[35]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Thiothixene and Nebivolol.	Hypertension [BA00-BA04]	[32]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Thiothixene and Levamlodipine.	Hypertension [BA00-BA04]	[32]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Thiothixene and TAK-491.	Hypertension [BA00-BA04]	[32]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Thiothixene and Clevidipine butyrate.	Hypertension [BA00-BA04]	[32]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[27]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Thiothixene and ITI-007.	Insomnia [7A00-7A0Z]	[27]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Thiothixene and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[36]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Thiothixene and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[37]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Thiothixene and Lasmiditan.	Migraine [8A80]	[38]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Thiothixene and Flibanserin.	Mood disorder [6A60-6E23]	[39]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Thiothixene and Lorcaserin.	Obesity [5B80-5B81]	[40]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Thiothixene and Lofexidine.	Opioid use disorder [6C43]	[32]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Thiothixene when combined with Opicapone.	Parkinsonism [8A00]	[41]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Methylscopolamine.	Peptic ulcer [DA61]	[27]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Thiothixene and Silodosin.	Prostate hyperplasia [GA90]	[32]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Thiothixene when combined with Neupro.	Restless legs syndrome [7A80]	[41]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Thiothixene and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[27]
-----------


⏷ Show the Full List of 30 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tiotixene 1 mg capsule	1 mg	Oral Capsule	Oral
Tiotixene 2 mg capsule	2 mg	Oral Capsule	Oral
Tiotixene 5 mg capsule	5 mg	Oral Capsule	Oral
Tiotixene 10 mg capsule	10 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 212).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070600.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64.
6	In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect. 2017 Mar 2;5(2):e00299.
7	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
8	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
9	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
10	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
11	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
12	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
13	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
15	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
16	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
17	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
18	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
19	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
20	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
21	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
22	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
23	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
24	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
25	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
26	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
27	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
28	Cerner Multum, Inc. "Canadian Product Information.".
29	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
30	Multum Information Services, Inc. Expert Review Panel.
31	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
32	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
33	Cerner Multum, Inc. "Australian Product Information.".
34	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
35	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
36	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
37	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
38	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
39	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
40	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
41	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]